Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery



Status:Active, not recruiting
Conditions:Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/8/2019
Start Date:April 2009

Use our guide to learn which trials are right for you!

A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma

PURPOSE: This phase II trial is studying how well gemcitabine and erlotinib work when given
before and after surgery in treating patients with pancreatic cancer that can be removed by
surgery. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Giving gemcitabine and erlotinib before surgery may make the tumor smaller and reduce
the amount of normal tissue that needs to be removed. Giving these drugs after surgery may
kill any tumor cells that remain after surgery.

This is a single arm, non-randomized phase II study. Eligible, fully registered patients will
receive preoperative chemotherapy consisting of gemcitabine plus erlotinib. Preoperative
chemotherapy will be followed by exploratory laparotomy and pancreaticoduodenectomy. Patients
will then receive postoperative chemotherapy consisting of gemcitabine plus erlotinib. Up to
123 patients will be accrued to this study, with the expectation that 78 patients will remain
fully eligible and evaluable for the primary endpoint. The primary and secondary objectives
for the study are listed below.

Primary Objective:

To estimate the proportion of patients alive at two years from the date of registration

Secondary Objectives:

1. To determine the resection rate (defined as the fraction of patients who proceed to
planned surgery with removal of primary tumor [R0/R1]) following induction treatment
with gemcitabine plus erlotinib

2. To estimate the time to disease progression/relapse

3. To evaluate the rate of R0, R1, and R2 resections (defined as per the 6th edition of the
AJCC Cancer Staging Manual) in patients treated with preoperative gemcitabine plus
erlotinib chemotherapy

4. To evaluate the toxicity profile of preoperative gemcitabine plus erlotinib and the
feasibility of postoperative gemcitabine plus erlotinib

5. To evaluate response rates to preoperative chemotherapy for patients treated with
preoperative gemcitabine and erlotinib

6. To identify molecular predictors of pancreatic cancer response to gemcitabine combined
with erlotinib

7. To identify genetic profiles of pancreatic adenocarcinoma that may be associated with
response to neoadjuvant therapy

After completion of postoperative chemotherapy treatment, patients are followed every 3
months for 2 years and then every 6 months for 2 years.

Eligibility Criteria:

1. Cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinate
process.

NOTE: Patients with tumors of the pancreatic neck, body or tail are not eligible.
Patients with evidence of neuroendocrine tumors, duodenal adenocarcinoma, or ampullary
adenocarcinoma are not eligible.

2. Localized, potentially resectable tumors as defined below. All patients must be staged
with a chest X-ray or CT, and abdominal CT (contrast-enhanced, helical thin-cut) or
MRI. Radiological resectability is defined by the following criteria on abdominal
imaging:

- No evidence of tumor extension to the celiac axis, hepatic artery, or superior
mesenteric artery

- No evidence of tumor encasement or occlusion of the superior mesenteric vein
(SMV) or the SMV/portal vein confluence

- No evidence of visceral or peritoneal metastases

NOTE: Patients with borderline resectable or marginally resectable pancreatic cancer
are not eligible. Patients must meet all objective imaging criteria outlined above.

3. ≥ 18 years of age

4. ECOG/Zubrod performance status of 0 or 1

5. Baseline weight loss ≤ 15% of premorbid weight

6. Patient must have adequate hematologic, renal, and hepatic function as defined by:

- WBC ≥ 2,000 cells/mm³

- ANC ≥ 1,500 cells/mm³

- Platelets ≥ 100,000 cells/mm³

- Serum bilirubin ≤ 2.5 mg/dL

- Serum creatinine ≤ 1.5 mg/dL or a calculated creatinine clearance of ≥ 50 ml/min
(24 hour urine collection)

- ALT < 2.5 times upper limit of normal (ULN)

- AST < 2.5 times ULN

- Albumin ≥ 3.2 g/dl

7. No history of the following:

- Prior EGFR targeted therapy or therapy for pancreatic cancer

- Active infection requiring intravenous antibiotics at the time of registration

8. Non-pregnant and non-breast feeding. Female participants of child bearing potential
must have a negative urine or serum pregnancy test prior to registration.
Perimenopausal participants must be amenorrheic ≥ 12 months to be considered not of
childbearing potential. All patients of reproductive potential must agree to use an
effective method of birth control while receiving study therapy.

9. No prior malignancy within 5 years of registration (Exceptions: non-melanoma skin
cancer, in-situ cancers)
We found this trial at
24
sites
Dayton, Ohio 45420
?
mi
from
Dayton, OH
Click here to add this to my saved trials
2401 West Belvedere Avenue
Baltimore, Maryland 21215
(410) 601-4688
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital The Alvin & Lois Lapidus Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
2500 N. State St.
Jackson, Mississippi 39216
(601) 815-6802
University of Mississippi Cancer Clinic he Cancer Institute is home to the ACT Tobacco Treatment,...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
900 Caton Ave.
Baltimore, Maryland 21229
410-368-6000
St. Agnes Hospital Cancer Center Saint Agnes Hospital is leading Maryland in the battle against...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bridgeport, Connecticut 06606
?
mi
from
Bridgeport, CT
Click here to add this to my saved trials
101 Manning Drive
Chapel Hill, North Carolina 27514
(919) 966-0000
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill One of the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
1 Wyoming St
Dayton, Ohio 45409
(937) 208-2300
?
mi
from
Dayton, OH
Click here to add this to my saved trials
9000 North Main Street
Dayton, Ohio 45415
(937) 734-5800
Samaritan North Cancer Care Center At Good Samaritan Hospital (GSH), our licensed, board-certified staff uses...
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Indianapolis, Indiana 46237
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Kettering, OH
Click here to add this to my saved trials
La Jolla, California 92093
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Lakeland, FL
Click here to add this to my saved trials
Los Angeles, California 90027
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Madison, WI
Click here to add this to my saved trials
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
160 E 34th St
New York, New York 10016
(212) 731-5001
NYU Cancer Institute at New York University Medical Center The Perlmutter Cancer Center takes a...
?
mi
from
New York, NY
Click here to add this to my saved trials
Newport News, Virginia 23606
?
mi
from
Newport News, VA
Click here to add this to my saved trials
8303 Dodge St
Omaha, Nebraska 68114
(402) 354-8124
Methodist Estabrook Cancer Center At Methodist Estabrook Cancer Center, we understand how deeply a diagnosis...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
4805 NE Glisan St
Portland, Oregon 97213
(503) 215-1111
Providence Cancer Center at Providence Portland Medical Center We strive to give those we serve...
?
mi
from
Portland, OR
Click here to add this to my saved trials
101 E Wood St
Spartanburg, South Carolina 29303
(864) 560-6000
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center Gibbs Cancer Center is a nationally...
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Toronto, Ontario
?
mi
from
Toronto,
Click here to add this to my saved trials
3130 N. County Rd. 25-A
Troy, Ohio 45373
(937) 440-4000
UVMC Cancer Care Center at Upper Valley Medical Center Upper Valley Medical Center (UVMC) is...
?
mi
from
Troy, OH
Click here to add this to my saved trials
?
mi
from
Tulsa, OK
Click here to add this to my saved trials